ObjectiveToexploretheclinicaleffectandsaftyinthetreatmentofpostherpeticneuralgia(PHN)by different administration route of extracts from rabbit skin inflamed by vaccinia virus for injection (ERSIVVI). Methods PHN patients were selected for study, all patients were divided into parapharyngeal administration group (PA group) and intravenous administration group (IV group) , which has 45 patients. The PA group was treated by paravertebral administration with 45 mL ERSIVVI (3 mL:3.6 IU)+195 mL 0.9%NS with-12 mL·h, and the IV group treated by ERSIVVI 9 mL intravenous infusion. Likert pain scale and QS sleep index were used to evaluate pain and sleep improvement before treatment, 1 day after treatment, at discharge, and after discharge. Results 90 cases of PHN patients were selected for study, which had been treated in our hospital during Sep 2014 to Nov 2016 and were divided into two group randomly, each group of 45 cases. Likert pain scores of two groups of patients one day after treatment, at discharge and one month after discharge were significant lower than before treatment (P <0.05). Compared with the IV group, the Likert pain score of PA group one day after treatmently was significantly decreased (P<0.05). QS sleep index score of two groups of patients one day after treatment, at discharge and one month after discharge were significant higher than before treatment (P <0.05). Compared with the Ⅳ group, the QS sleep index score of PA group,after 1 day of treatment was significantly increased (P<0.05). The clinical efficacy of the PA group was significant higher than Ⅳ group, the significant efficiency of PA group was significantly higher (P<0.05). During treat-ment periods, there was one case of dizziness, nausea and slight increase of blood pressure in the Ⅳ group. After 15 min of withdrawal, the above symptoms were relieved. In the course of subsequent treatment the patients did not show any of the above symptoms. Conclusion The efficacy of ERSIVVI in the treatment of herpes zoster by par-avertebralinjection is clear, with few adverse reactions.%目的探讨牛痘疫苗致炎兔皮提取物注射液(ERSIVVI)经不同给药途径治疗带状疱疹后遗神经痛(PHN)的临床效果与安全性.方法以PHN患者为研究对象,分为椎旁组(PA组)和静脉组(Ⅳ组),分别予椎旁给药[ERSIVVI(3 mL:3.6 IU)45 mL+195 mL 0.9%NS配泵,2 mL·h-1)]和ERSIVVI 9 mL静脉滴注.于治疗前、治疗后1日、出院时及出院后采用Likert疼痛量表评分和QS睡眠指数评分评估患者疼痛程度及睡眠改善情况.结果最终选取2014年9月到2016年11月在我院就诊的90例PHN患者为研究对象,随机分为两组,每组45例.两组患者治疗后1日、出院时、出院后1月Likert疼痛评分均较治疗前显著降低(P<0.05),与IV组相比较,PA组治疗后1日Likert疼痛评分降低的更为明显(P<0.05);两组患者治疗后1日、出院时、出院后1月QS睡眠指数评分显著高于治疗前(P<0.05),与Ⅳ组相比较,PA组治疗后1日QS睡眠指数评分升高的更为明显(P<0.05).两组患者临床疗效总体以PA组较高,PA组显效率显著高于Ⅳ组(P<0.05).治疗过程中Ⅳ有1例患者出现头晕、恶心、血压轻度升高,停药15 min后上述症状缓解,之后继续给药患者未出现上述不适,其余患者未见明显不良反应.结论ERSIVVI经椎旁给药治疗带状疱疹的疗效明确、不良反应少.
展开▼
